Leveraging CNS PK & Biodistribution to Inform ASO Dosing

By | 16 January 2026
  • Interpreting CNS exposure and tissue distribution across species
  • Translating preclinical PK into human dose and dosing frequency
  • Balancing effective target engagement with safety margins